Pyxis has an in-license agreement with Pfizer to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203. The company is also advancing PYX-107, a CD40 agonist in Phase 2 development for soft tissue sarcomas, esophageal, and pancreatic cancers. The company believes that antibody-drug conjugates and immunotherapies offer unique potential to address difficult-to-treat cancers.
Cyborg Score Rationale
With a market capitalization up to $300 million, Pyxis is in the micro-cap category. While analysts project a one-year price target of $7.32 with a range of $5.05 to $9.45, the company remains clinical-stage with execution risk tied to Phase 1/2 trial outcomes. Recent positive preliminary Phase 1 data for lead candidate MICVO showed significant response rates but also raised safety concerns.
Top Insights
December 2025: Announced positive preliminary Phase 1 data for Micvotabart Pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma
Strategic partnership with Pfizer for multiple ADC programs reduces development risk and brings commercial infrastructure
Diversified pipeline with PYX-107 CD40 agonist in Phase 2 across multiple solid tumor indications
Portfolio strategy targets both direct tumor cell killing and immune suppression pathways